Top

Published in:

01-07-2014 | Correspondence

Improved health-related quality of life outcomes associated with SHH subgroup medulloblastoma in SIOP-UKCCSG PNET3 trial survivors

Authors: Kim S. Bull, Colin R. Kennedy, Simon Bailey, David W. Ellison, Steven C. Clifford

Published in: Acta Neuropathologica | Issue 1/2014

Excerpt

Reduced health-related quality of life (HRQoL), including impaired cognitive, social, physical, behavioural and emotional functioning, is common in children treated for medulloblastoma [1, 2, 7] and has been associated with clinical factors such as surgical resection and treatment modality [2, 5, 6]. Recent biological advances have allowed the distinction of medulloblastomas into four consensus molecular subgroups—WNT, SHH, Group 3 and Group 4—which display distinct molecular, clinical, and pathological disease characteristics [3, 4, 8, 9]. Together, these observations raise the hypothesis that HRQoL in medulloblastoma survivors may be related to their underlying tumour biology. …

Available only for authorised users

Bhat SR, Goodwin TL, Burwinkle TM et al (2005) Profile of daily life in children with brain tumors: an assessment of health-related quality of life. J Clin Oncol 23:5493–5500PubMedCrossRef

Bull KS, Spoudeas HA, Yadegarfar G et al (2007) Reduction of health status 7 years after addition of chemotherapy to craniospinal irradiation for medulloblastoma: a follow-up study in PNET 3 trial survivors—On behalf of the CCLG (formerly UKCCSG). J Clin Oncol 25:4239–4245PubMedCrossRef

Ellison DW, Dalton J, Kocak M et al (2011) Medulloblastoma: clinicopathological correlates of SHH, WNT, and non-SHH/WNT molecular subgroups. Acta Neuropathol 121:381–396PubMedCentralPubMedCrossRef

Ellison DW, Kocak M, Dalton J et al (2011) Definition of disease-risk stratification groups in childhood medulloblastoma using combined clinical, pathologic, and molecular variables. J Clin Oncol 29:1400–1407PubMedCentralPubMedCrossRef

Kennedy C, Bull K, Chevignard M et al (2014) Quality of survival and growth in children and young adults in the PNET4 European controlled trial of hyperfractionated versus conventional radiation therapy for standard-risk medulloblastoma. Int J Radiat Oncol Biol Phys 88:292–300PubMedCrossRef

Konczak J, Schoch B, Dimitrova A et al (2005) Functional recovery of children and adolescents after cerebellar tumour resection. Brain 128:1428–1441PubMedCrossRef

Palmer SL, Armstrong C, Onar-Thomas A et al (2013) Processing speed, attention, and working memory after treatment for medulloblastoma: an international, prospective, and longitudinal study. J Clin Oncol 31:3494–3500PubMedCrossRef

Schwalbe EC, Williamson D, Lindsey JC et al (2013) DNA methylation profiling of medulloblastoma allows robust subclassification and improved outcome prediction using formalin-fixed biopsies. Acta Neuropathol 125:359–371PubMedCrossRef

Taylor MD, Northcott PA, Korshunov A et al (2012) Molecular subgroups of medulloblastoma: the current consensus. Acta Neuropathol 123:465–472PubMedCentralPubMedCrossRef

10.

Taylor RE, Bailey CC, Robinson K et al (2003) Results of a randomized study of pre-radiation chemotherapy versus radiotherapy alone for non-metastatic medulloblastoma: the International Society of Paediatric Oncology United Kingdom Children’s Cancer Study Group PNET-3 study. J Clin Oncol 21:1581–1591PubMedCrossRef

11.

Wefers AK, Warmuth-Metz M, Pöschl J et al (2014) Subgroup-specific localization of human medulloblastoma based on pre-operative MRI. Acta Neuropathol 127:931–933PubMedCrossRef

Title: Improved health-related quality of life outcomes associated with SHH subgroup medulloblastoma in SIOP-UKCCSG PNET3 trial survivors
Authors: Kim S. Bull
Colin R. Kennedy
Simon Bailey
David W. Ellison
Steven C. Clifford
Publication date: 01-07-2014
Publisher: Springer Berlin Heidelberg
Published in: Acta Neuropathologica / Issue 1/2014
Print ISSN: 0001-6322
Electronic ISSN: 1432-0533
DOI: https://doi.org/10.1007/s00401-014-1300-4

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Improved health-related quality of life outcomes associated with SHH subgroup medulloblastoma in SIOP-UKCCSG PNET3 trial survivors

Excerpt

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2014

Epilepsies associated with focal cortical dysplasias (FCDs)

Genomic and transcriptomic analyses match medulloblastoma mouse models to their human counterparts

Pituitary blastoma: a pathognomonic feature of germ-line DICER1 mutations

Rapid-onset dystonia-parkinsonism associated with the I758S mutation of the ATP1A3 gene: a neuropathologic and neuroanatomical study of four siblings

Cerebral cavernous malformations in the setting of focal epilepsies: pathological findings, clinical characteristics, and surgical treatment principles

Tau protein mutation P364S in two sisters: clinical course and neuropathology with emphasis on new, composite neuronal tau inclusions